WO2003055979A3 - Anticorps se liant à blys selon un mode immunospécifique - Google Patents

Anticorps se liant à blys selon un mode immunospécifique

Info

Publication number
WO2003055979A3
WO2003055979A3 PCT/US2002/036496 US0236496W WO03055979A3 WO 2003055979 A3 WO2003055979 A3 WO 2003055979A3 US 0236496 W US0236496 W US 0236496W WO 03055979 A3 WO03055979 A3 WO 03055979A3
Authority
WO
WIPO (PCT)
Prior art keywords
blys
antibodies
immunospecifically bind
present
related molecules
Prior art date
Application number
PCT/US2002/036496
Other languages
English (en)
Other versions
WO2003055979A2 (fr
Inventor
Steven M Ruben
Steven C Barash
Gil H Choi
Tristan J Vaughan
David Hilbert
Original Assignee
Human Genome Sciences Inc
Steven M Ruben
Steven C Barash
Gil H Choi
Tristan J Vaughan
David Hilbert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Steven M Ruben, Steven C Barash, Gil H Choi, Tristan J Vaughan, David Hilbert filed Critical Human Genome Sciences Inc
Priority to EP02802570A priority Critical patent/EP1456347A4/fr
Priority to CA002467521A priority patent/CA2467521A1/fr
Priority to AU2002364954A priority patent/AU2002364954A1/en
Publication of WO2003055979A2 publication Critical patent/WO2003055979A2/fr
Publication of WO2003055979A3 publication Critical patent/WO2003055979A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

la présente invention concerne des anticorps et molécules connexes qui se lient à BLyS selon un mode immunospécifique. Elle concerne également des méthodes et des compositions permettant de détecter ou de diagnostiquer une pathologie ou des troubles en rapport avec une expression aberrante de BLyS, ou avec une fonction inappropriée de BLyS, Ces compositions renferment des anticorps ou des fragments ou des variants de BLyS, ou bien des molécules connexes qui se lient à BLyS selon un mode immunospécifique. Cette invention concerne en outre des méthodes ou des compositions permettant de prévenir, de traiter ou d'atténuer une pathologie ou des troubles en rapport avec une expression aberrante de BLyS, ou avec une fonction inappropriée de BLyS, par administration à un animal d'une dose efficace d'un ou plusieurs anticorps ou fragments d'anticorps, ou bien de molécules connexes se liant à BLyS selon un mode immunospécifique.
PCT/US2002/036496 2001-11-16 2002-11-14 Anticorps se liant à blys selon un mode immunospécifique WO2003055979A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP02802570A EP1456347A4 (fr) 2001-11-16 2002-11-14 Anticorps se liant a blys selon un mode immunospecifique
CA002467521A CA2467521A1 (fr) 2001-11-16 2002-11-14 Anticorps se liant a blys selon un mode immunospecifique
AU2002364954A AU2002364954A1 (en) 2001-11-16 2002-11-14 ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33146901P 2001-11-16 2001-11-16
US60/331,469 2001-11-16
US34081701P 2001-12-19 2001-12-19
US60/340,817 2001-12-19

Publications (2)

Publication Number Publication Date
WO2003055979A2 WO2003055979A2 (fr) 2003-07-10
WO2003055979A3 true WO2003055979A3 (fr) 2003-12-18

Family

ID=26987779

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036496 WO2003055979A2 (fr) 2001-11-16 2002-11-14 Anticorps se liant à blys selon un mode immunospécifique

Country Status (4)

Country Link
EP (1) EP1456347A4 (fr)
AU (1) AU2002364954A1 (fr)
CA (1) CA2467521A1 (fr)
WO (1) WO2003055979A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
EP2319527A3 (fr) 1999-01-25 2011-10-12 Biogen Idec MA Inc. BAFF, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules B et des immunoglobulines
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
GEP20053685B (en) 1999-08-17 2005-12-12 Biogen Inc BAFF Receptor (BCMA), an Immunoregulatory Agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
PT2281843T (pt) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
KR20060027801A (ko) 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
WO2005012531A2 (fr) * 2003-08-01 2005-02-10 Genentech, Inc. Polypeptides de liaison avec sequences de diversite restreinte
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
KR100923828B1 (ko) * 2004-03-31 2009-10-27 캐논 가부시끼가이샤 금-결합성 단백질
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
JP5570681B2 (ja) * 2004-08-31 2014-08-13 興和株式会社 抗ヒトｂａｆｆ抗体
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006344395B2 (en) 2005-10-13 2013-05-02 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive diseases
WO2007062090A2 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
TW200831528A (en) * 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
EP2139517B1 (fr) 2007-03-27 2013-05-29 Zymogenetics, Inc. Combinaison d'inhibition de blys et mofetil de mycophenolate destinés au traitement de maladies autoimmunes
TWI489993B (zh) 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
JP2011500715A (ja) 2007-10-16 2011-01-06 ザイモジェネティクス， インコーポレイテッド 自己免疫疾患の治療のためのＢＬｙＳ阻害剤および抗ＣＤ２０剤の組合せ
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes
CN103421113B (zh) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
CN107586339B (zh) * 2016-07-06 2023-01-20 尚华科创投资管理（江苏）有限公司 一种BLyS抗体及其制备方法和应用
EP3576790A4 (fr) 2017-02-01 2020-12-23 Yale University Traitement de la résistance aux diurétiques
CN111787950A (zh) 2018-01-05 2020-10-16 科威迪亚治疗公司 用于无免疫抑制地治疗il-6介导的炎症的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087977A2 (fr) * 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2396793A1 (fr) * 2000-02-16 2001-08-23 Genentech, Inc. Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf
PT2281843T (pt) * 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087977A2 (fr) * 2000-05-12 2001-11-22 Amgen Inc. Procedes et compositions d'une matiere relative a april/g70, bcma, blys/agp-3, et taci
US20030012783A1 (en) * 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1456347A4 *

Also Published As

Publication number Publication date
AU2002364954A8 (en) 2003-07-15
AU2002364954A1 (en) 2003-07-15
CA2467521A1 (fr) 2003-07-10
EP1456347A2 (fr) 2004-09-15
WO2003055979A2 (fr) 2003-07-10
EP1456347A4 (fr) 2006-08-02

Similar Documents

Publication Publication Date Title
WO2003055979A3 (fr) Anticorps se liant à blys selon un mode immunospécifique
MXPA02012434A (es) Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii.
WO2002016411A3 (fr) Polypeptides de fixation et procedes associes
WO2003054216A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs trail
ATE470676T1 (de) Anti-vegf-2 antikörper
WO2002097033A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs de trail
WO2002094192A3 (fr) Anticorps contre le facteur de necrose tumorale delta (april)
BRPI0410129A (pt) uso terapêutico de anticorpos anti-cs1
WO2002083849A3 (fr) Facteur de croissance endothélial vasculaire 2
WO2003057006A3 (fr) Utilisation d'anticorps diriges contre l'antigene muc18
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
WO2004013287A3 (fr) Anticorps diriges contre le recepteur c3a
WO2003085093A3 (fr) Anticorps se liant specifiquement a gmad
WO2004069183A3 (fr) Regulation immunitaire basee sur le ciblage de molecules d'activation precoce
BRPI0413404A (pt) composições farmacêuticas, métodos de tratamento ou prevenção de disfunções cardìacas, métodos de aumento da função cardìaca e método de identificação de inibidor de mif
WO2004003144A3 (fr) Anticorps qui se lient specifiquement a reg iv
WO2005016236A3 (fr) Anticorps se liant de maniere immunospecifique aux recepteurs trail
WO2002079377A3 (fr) Anticorps a liaison immunospecifique avec les recepteurs 'trail'
WO2004016753A3 (fr) Anticorps se fixant de facon immunospecifique a des recepteurs trail
WO2003042367A3 (fr) Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail
WO2003086301A3 (fr) Anticorps se liant specifiquement a tr2
WO2002070563A3 (fr) Domaine de liaison de ligand au recepteur hormonal nucleaire
WO2002101394A3 (fr) Procede de criblage a l'aide des proteines bnpi et dnpi

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2467521

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002802570

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002802570

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP